ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions
View by Date

Monday, November 14, 2016

9:00AM-11:00AM
Abstract Number: 1658
Regulatory Role of  the IL-9/IL-9R System  on Pannus Formation in Psoriatic Arthritis
Spondylarthropathies Psoriatic Arthritis – Pathogenesis, Etiology - Poster I
9:00AM-11:00AM
Abstract Number: 1927
Relapses in Patients with ANCA-Associated Vasculitis: A Retrospective Study on Severity and Organ Involvement Compared to Initial Onset
Vasculitis - Poster II: ANCA-Associated Vasculitis
9:00AM-11:00AM
Abstract Number: 1572
Relationship Between KDR (VEGFR2) Gene Polymorphisms and Serum KDR Protein Levels in Patients with Rheumatoid Arthritis
Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster II
9:00AM-11:00AM
Abstract Number: 1333
Relevance of Granulomatous Presentation for the Diagnosis and Outcome of Uveitis: Retrospective Case-Control Study of 251 Patients
Miscellaneous Rheumatic and Inflammatory Diseases - Poster II
9:00AM-11:00AM
Abstract Number: 1261
Reliability and Validity of the Patient Health Questionnaire-9 for Assessment of Depression in Socioeconomically Disadvantaged Latinos with Rheumatoid Arthritis Living in the United States
Healthcare Disparities in Rheumatology - ARHP Poster
9:00AM-11:00AM
Abstract Number: 1888
Reliability, Validity, and Sensitivity to Change of the Simplified Duruoz Hand Index in Systemic Sclerosis
Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster II
9:00AM-11:00AM
Abstract Number: 1779
Remission and Low Lupus Disease Activity Status (LLDAS) Protect Lupus Patients from Damage Occurrence: Data from a Multi-Ethnic, Multinational Latin American Lupus Cohort
Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life
9:00AM-11:00AM
Abstract Number: 1358
Response of Hidradenitis Suppurativa to Biologic Therapy
Miscellaneous Rheumatic and Inflammatory Diseases - Poster II
9:00AM-11:00AM
Abstract Number: 1421
Responsiveness of Lupus Impact Tracker Among Chinese Patients with Lupus
Quality Measures and Quality of Care - Poster II
9:00AM-11:00AM
Abstract Number: 1191
Retinal Vessel Morphometry Associations with Polymyalgia Rheumatica; Findings from the European Prospective Investigation of Cancer (EPIC) in Norfolk
Epidemiology and Public Health - Poster II
9:00AM-11:00AM
Abstract Number: 1941
Retrospective Survey of Concomitant Autoimmune Diseases and Autoantibodies in a Cohort of Patients with ANCA-Associated Vasculitis (AAV)
Vasculitis - Poster II: ANCA-Associated Vasculitis
9:00AM-11:00AM
Abstract Number: 1138
Rheumapalooza Update: Applying a Flipped Classroom Instructional Model to an Intensive Rheumatology Curriculum for Second Year Medical Students
Education - Poster
9:00AM-11:00AM
Abstract Number: 1341
Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Literature Review
Miscellaneous Rheumatic and Inflammatory Diseases - Poster II
9:00AM-11:00AM
Abstract Number: 1339
Rheumatic Immune Related Adverse Events of Checkpoint Therapy for Cancer: Case Series of a New Nosologic Entity
Miscellaneous Rheumatic and Inflammatory Diseases - Poster II
9:00AM-11:00AM
Abstract Number: 1549
Rheumatoid Arthritis and Periodontal Disease: Salivary ACPA Levels and Clinical Presentation
Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications
  • «Previous Page
  • 1
  • …
  • 43
  • 44
  • 45
  • 46
  • 47
  • …
  • 68
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology